DOCSLIB.ORG

M2021: Pharmacogenetic Testing

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
M2021: Pharmacogenetic Testing Pharmacogenetic Testing Policy Number: AHS – M2021 – Pharmacogenetic Prior Policy Name and Number, as applicable: Testing • M2021 – Cytochrome P450 Initial Presentation Date: 06/16/2021 Revision Date: N/A I. Policy Description Pharmacogenetics is defined as the study of variability in drug response due to heredity (Nebert, 1999). Cytochrome (CYP) P450 enzymes are a class of enzymes essential in the synthesis and breakdown metabolism of various molecules and chemicals. Found primarily in the liver, these enzymes are also essential for the metabolism of many medications. CYP P450 are essential to produce many biochemical building blocks, such as cholesterol, fatty acids, and bile acids. Additional cytochrome P450 are involved in the metabolism of drugs, carcinogens, and internal substances, such as toxins formed within cells. Mutations in CYP P450 genes can result in the inability to properly metabolize medications and other substances, leading to increased levels of toxic substances in the body. Approximately 58 CYP genes are in humans (Bains, 2013; Tantisira & Weiss, 2019). Thiopurine methyltransferase (TPMT) is an enzyme that methylates azathioprine, mercaptopurine and thioguanine into active thioguanine nucleotide metabolites. Azathioprine and mercaptopurine are used for treatment of nonmalignant immunologic disorders; mercaptopurine is used for treatment of lymphoid malignancies; and thioguanine is used for treatment of myeloid leukemias (Relling et al., 2011). Dihydropyrimidine dehydrogenase (DPD), encoded by the gene DPYD, is a rate-limiting enzyme responsible for fluoropyrimidine catabolism. The fluoropyrimidines (5-fluorouracil and capecitabine) are drugs used in the treatment of solid tumors, such as colorectal, breast, and aerodigestive tract tumors (Amstutz et al., 2018). A variety of cell surface proteins, such as antigen-presenting molecules and other proteins, are encoded by the human leukocyte antigen genes (HLAs). HLAs are also known as major histocompatibility complex (MHC) (Viatte, 2017). II. Related Policies Policy Number Policy Title AHS-G2100 In Vitro Chemoresistance and Chemosensitivity Assays M2021 Pharmacogenetic Testing Page 1 of 58 AHS-G2115 Metabolite Markers of Thiopurines Testing AHS-M2030 Testing for Targeted Therapy of Non-Small-Cell Lung Cancer AHS-M2067 Therapeutic Drug Monitoring for 5-Fluorouracil AHS-M2082 Genetic Testing for Lipoprotein A Variant(s) as a Decision Aid for Aspirin Treatment and/or CVD Risk Assessment AHS-M2109 Molecular Panel Testing of Cancers for Diagnosis, Prognosis, and Identification of Targeted Therapy III. Indications and/or Limitations of Coverage Application of coverage criteria is dependent upon an individual’s benefit coverage at the time of the request 1. Testing for the CYP2D6 genotype once per lifetime (please see policy guideline)* IS MEDICALLY NECESSARY for individuals being considered for therapy with any of the medications listed below, or who are in their course of therapy with a medication listed below, to aid in therapy selection and/or dosing. a. Amphetamine b. Aripiprazole c. Aripiprazole Lauroxil d. Atomoxetine e. Brexpiprazole f. Carvedilol g. Cevimeline h. Clozapine i. Codeine j. Desipramine k. Deutetrabenazine l. Eligustat M2021 Pharmacogenetic Testing Page 2 of 58 m. Fluvoxamine n. Gefitinib o. Iloperidone p. Lofexidine q. Meclizine r. Metoclopramide s. Nortriptyline t. Ondansetron u. Paroxetine v. Perphenazine w. Pimozide x. Propafenone y. Tamoxifen z. Tetrabenazine aa. Thioridazine bb. Tolterodine cc. Tramadol dd. Tropisetron ee. Valbenazine ff. Venlafaxine gg. Vortioxetine 2. Testing for the CYP2D6 and CYP2C19 genotype once per lifetime (please see policy guideline)* IS MEDICALLY NECESSARY for individuals being considered for therapy with any of the medications listed below, or who are in their course of therapy with these medications, to aid in therapy selection and/or dosing. a. Amitriptyline b. Clomipramine c. Doxepin d. Imipramine e. Trimipramine 3. Testing for the CYP2C19 genotype once per lifetime (please see policy guideline)* IS MEDICALLY NECESSARY for individuals being considered for therapy with any of the M2021 Pharmacogenetic Testing Page 3 of 58 medications listed below, or who are in their course of therapy with these medications, to aid in therapy selection and/or dosing. a. Brivaracetam b. Citalopram c. Clobazam d. Clopidogrel e. Escitalopram f. Flibanserin g. Pantoprazole (in pediatric individuals) h. Sertraline i. Voriconazole 4. Testing for the CYP2C9 genotype once per lifetime (please see policy guideline)* IS MEDICALLY NECESSARY for individuals being considered for therapy with any of the medications listed below, or who are in their course of therapy with these medications, to aid in therapy selection and/or dosing. a. Celecoxib b. Dronabinol c. Erdafitinib d. Flurbiprofen e. Piroxicam f. Siponimod 5. Testing for the CYP2C9, CYP4F2, VKORC1, and rs12777823 genotype once per lifetime IS MEDICALLY NECESSARY for individuals being considered for Warfarin therapy. 6. Testing for the TPMT and NUDT15 genotype once per lifetime (please see policy guideline)* IS MEDICALLY NECESSARY for individuals being considered for therapy with the below medications, or who are in their course of therapy with these medications, to aid in therapy selection and/or dosing. a. Azathioprine M2021 Pharmacogenetic Testing Page 4 of 58 b. Mercaptopurine c. Thioguanine 7. Testing for the DPYD genotype once per lifetime (please see policy guideline)* IS MEDICALLY NECESSARY for individuals being considered for therapy with the below medications, or who are in their course of therapy with these medications, to aid in therapy selection and/or dosing. a. Capecitabine b. Fluorouracil 8. Testing for the following Human Leukocyte Antigens (HLAs) genotypes once per lifetime IS MEDICALLY NECESSARY for individuals being considered for therapy with the below medications, or who are in their course of therapy with these medications, to aid in therapy selection and/or dosing: a. HLA-B*57:01 before treatment with Abacavir b. HLA-B*58:01 before treatment with Allopurinol c. HLA-B*15:02 for treatment with Oxcarbazepine d. HLA-B*15:02 and HLA-A*31:01 for treatment with Carbamazepine 9. Testing for the CYP2C9 and HLA-B*15:02 genotype once per lifetime IS MEDICALLY NECESSARY for individuals being considered for therapy with the below medication, or who are in their course of therapy with this medication, to aid in therapy selection and/or dosing. a. Phenytoin 10. Testing for the G6PD genotype once per lifetime (please see policy guideline)* IS MEDICALLY NECESSARY for individuals being considered for therapy with the medications listed below, or who are in their course of therapy with these medications, to aid in therapy selection and/or dosing. a. Pegloticase b. Primaquine c. Rasburicase d. Tafenoquine M2021 Pharmacogenetic Testing Page 5 of 58 11. Testing for the following genotypes once per lifetime (please see policy guideline)* IS MEDICALLY NECESSARY for individuals being considered for therapy with the below medications, or who are in their course of therapy with a medication listed below, to aid in therapy selection and/or dosing. a. BCHE for treatment with mivacurium or succinylcholine b. CFTR for treatment with Ivacaftor, Elexacaftor and Tezacaftor, Ivacaftor and Lumacaftor, or Ivacaftor and Tezacaftor c. CYP2B6 for treatment with Efavirenz d. CYP3A5 for treatment with Tacrolimus e. IFNL3 treatment with Peginterferon alfa-2a, Peginterferon alfa-2b or Ribavirin f. NAT2 for treatment with Amifampridine or Amifampridine Phosphate g. UGT1A1 for treatment with Atazanavir, Belinostat, Irinotecan, Nilotinib, or Pazopanib 12. Testing for the RYR1 and CACNA1S genotype once per lifetime (please see policy guideline)* IS MEDICALLY NECESSARY for individuals being considered for the use of depolarizing muscle relaxants, such as succinylcholine, or halogenated volatile anesthetics. 13. Genetic testing for the presence of variants in the SLCO1B1 gene for the purpose of identifying patients at risk of statin-induced myopathy IS NOT MEDICALLY NECESSARY. The following does not meet coverage criteria due to a lack of available published scientific literature confirming that the test(s) is/are required and beneficial for the diagnosis and treatment of a patient’s illness. 14. The following pharmacogenetic testing IS INVESTIGATIONAL: a. Genotyping for any medication therapy more than once per lifetime (please see policy guideline). * b. Testing for the specific genotype for individuals on medications not listed as meeting coverage criteria for testing. c. Testing for all other genotypes including, but not limited to, use of other medication therapy not listed as meeting coverage criteria. d. Genotyping the general population. e. Pharmacogenetic panel testing for individuals not being considered for any of the above conditions. M2021 Pharmacogenetic Testing Page 6 of 58 15. All other single nucleotide polymorphism (SNP) testing, either as individual SNPs or as a panel of SNPs, IS INVESTIGATIONAL for all indications. The list of SNPs includes, but is not limited to, the following: a. 5HT2C (serotonin receptor) b. 5HT2A (serotonin receptor) c. SLC6A4 (serotonin transporter) d. DRD1 (dopamine receptor) e. DRD2 (dopamine receptor) f. DRD4 (dopamine receptor) g. DAT1 or SLC6A3 (dopamine transporter) h. DBH (dopamine beta-hydroxylase) i. COMT (catechol-O-methyl-transferase) j. MTHFR (methylenetetrahydrofolate reductase) k. γ-Aminobutyric acid (GABA) A receptor l. OPRM1 (µ-opioid receptor)
Load more

Recommended publications
  • 2020 Prior Authorization Criteria
    2020 PRIOR AUTHORIZATION CRITERIA TABLE OF CONTENTS abiraterone tablet ...................................................................................................................... 217 ABRAXANE .............................................................................................................................. 131 ACTIMMUNE .............................................................................................................................. 14 ADASUVE ................................................................................................................................... 27 ADEMPAS ................................................................................................................................ 197 AFINITOR ................................................................................................................................. 217 AFINITOR DISPERZ ................................................................................................................. 217 AIMOVIG ..................................................................................................................................... 15 ALECENSA ............................................................................................................................... 217 ALIMTA ..................................................................................................................................... 131 ALIQOPA .................................................................................................................................
    [Show full text]
  • Pindolol of the Activation of Postsynaptic 5-HT1A Receptors
    Potentiation by (-)Pindolol of the Activation of Postsynaptic 5-HT1A Receptors Induced by Venlafaxine Jean-Claude Béïque, Ph.D., Pierre Blier, M.D., Ph.D., Claude de Montigny, M.D., Ph.D., and Guy Debonnel, M.D. The increase of extracellular 5-HT in brain terminal regions antagonist WAY 100635 (100 ␮g/kg, i.v.). A short-term produced by the acute administration of 5-HT reuptake treatment with VLX (20 mg/kg/day ϫ 2 days) resulted in a inhibitors (SSRI’s) is hampered by the activation of ca. 90% suppression of the firing activity of 5-HT neurons somatodendritic 5-HT1A autoreceptors in the raphe nuclei. in the dorsal raphe nucleus. This was prevented by the The present in vivo electrophysiological studies were coadministration of (-)pindolol (15 mg/kg/day ϫ 2 days). undertaken, in the rat, to assess the effects of the Taken together, these results indicate that (-)pindolol coadministration of venlafaxine, a dual 5-HT/NE reuptake potentiated the activation of postsynaptic 5-HT1A receptors inhibitor, and (-)pindolol on pre- and postsynaptic 5-HT1A resulting from 5-HT reuptake inhibition probably by receptor function. The acute administration of venlafaxine blocking the somatodendritic 5-HT1A autoreceptor, but not and of the SSRI paroxetine (5 mg/kg, i.v.) induced a its postsynaptic congener. These results support and extend suppression of the firing activity of dorsal hippocampus CA3 previous findings providing a biological substratum for the pyramidal neurons. This effect of venlafaxine was markedly efficacy of pindolol as an accelerating strategy in major potentiated by a pretreatment with (-)pindolol (15 mg/kg, depression.
    [Show full text]
  • Drug Class Review Beta Adrenergic Blockers
    Drug Class Review Beta Adrenergic Blockers Final Report Update 4 July 2009 Update 3: September 2007 Update 2: May 2005 Update 1: September 2004 Original Report: September 2003 The literature on this topic is scanned periodically. The purpose of this report is to make available information regarding the comparative effectiveness and safety profiles of different drugs within pharmaceutical classes. Reports are not usage guidelines, nor should they be read as an endorsement of, or recommendation for, any particular drug, use, or approach. Oregon Health & Science University does not recommend or endorse any guideline or recommendation developed by users of these reports. Mark Helfand, MD, MPH Kim Peterson, MS Vivian Christensen, PhD Tracy Dana, MLS Sujata Thakurta, MPA:HA Drug Effectiveness Review Project Marian McDonagh, PharmD, Principal Investigator Oregon Evidence-based Practice Center Mark Helfand, MD, MPH, Director Oregon Health & Science University Copyright © 2009 by Oregon Health & Science University Portland, Oregon 97239. All rights reserved. Final Report Update 4 Drug Effectiveness Review Project TABLE OF CONTENTS INTRODUCTION .......................................................................................................................... 6 Purpose and Limitations of Evidence Reports........................................................................................ 8 Scope and Key Questions .................................................................................................................... 10 METHODS.................................................................................................................................
    [Show full text]
  • ZHONG-THESIS-2016.Pdf
    ANTIDEPRESSANTMINING AZ AMAZ DESIGNING A WEBBASED ALGORITHM AND VISUAL LANGUAGE FOR ANTIDEPRESSANT DRUG SELECTION TO EDUCATE PRIMARY CARE PRACTITIONERS By Amy Zhong A thesis submitted to Johns Hopkins University in conformity with the requirements for the degree of Master of Arts Baltimore, Maryland March, 2016 © 2016 Amy Zhong All Rights Reserved ABSTRACT Depression is a common mental disorder that affects approximately 14.8 million American adults each year. In addition to being a debilitating condition, depression often occurs in tandem with other medical conditions such as diabetes, heart disease, and cancer. While psychiatric professionals are essential for the management of mental health, majority of patients seek care from their primary care practitioners. This phenomenon is of great concern because diagnosis of depression within primary care settings has only been accurate 25-50% of the time. The antidepressant drug selection algorithm utilizes a unique formula to integrate patient and family medical histories, patient symptoms, and patient preferences to make optimal treatment selections. The development of a visual language explores the use of graphic elements to improve understanding of major pharmacological mechanisms, knowledge essential to making rational DQWLGHSUHVVDQWGUXJVHOHFWLRQV,QFUHDWLQJWKLVPRELOHZHEEDVHGDSSOLFDWLRQZHKRSHWR¿OOD void in resources available to primary care practitioners, and improve management of mental health within the primary care setting. By Amy Zhong Chairpersons of the Supervisory Committee Adam I. Kaplin, M.D., Ph.D., esis Preceptor Assistant Professor, Departments of Psychiatry and Neurology e Johns Hopkins University School of Medicine Kristen Rahn Hollinger, Ph.D., esis Preceptor Instructor, Departments of Psychiatry and Neurology e Johns Hopkins University School of Medicine Jennifer E.
    [Show full text]
  • ( 12 ) United States Patent
    US010376507B2 (12 ) United States Patent (10 ) Patent No. : US 10 , 376 , 507 B2 Srinivasan et al. (45 ) Date of Patent: Aug. 13 , 2019 CRESEMBA® ( isavuconazonium sulfate ) , Highlights of Prescrib (54 ) METHOD OF TREATING A PATIENT WITH ing Information , Label ; Patient Information approved by the U . S . A CYP3A4 SUBSTRATE DRUG Food and Drug Administration ; Astellas Pharma US , Inc. ( Licensed from Basilea Pharmaceutics International Ltd . ) , Illinois, USA , Ini (71 ) Applicant: Bow River LLC , Corona Del Mar , CA tial U . S . Approval: 2015 , Revised Mar. 2015 , Reference ID : 3712237, ( US ) 28 pages . DIFLUCAN® ( fluconazole ), Label ; Patient Information , Reference ( 72 ) Inventors : Sundar Srinivasan , Corona Del Mar, ID : 3650838 , Roerig , Division of Pfizer Inc ., New York , NY, Revised Mar. 2013 , 35 pages. CA (US ) ; Christina Chow , Seattle , WA NIZORAL® (ketoconazole )Label ; Patient Information approved by (US ) the U . S . Food and Drug Administration , Reference ID : 3458324 , Copyright 2014 Janssen Pharmaceuticals, Inc . , New Jersey, USA , ( 73 ) Assignee : BOW RIVER LLC , Corona del Mar , Revised Feb . 2014 , 23 pages . NOXAFIL® (posaconazole ) , Highlights of Prescribing Informa CA (US ) tion , Label ; Patient Information approved by the U . S . Food and Drug Administration ; Copyright © 2006 , 2010 , 2013 , 2014 Merck ( * ) Notice : Subject to any disclaimer , the term of this Sharp & Dohme Corp . , a subsidiary of Merck & Co ., Inc ., New patent is extended or adjusted under 35 Jersey , USA , Revised Sep . 2016 , Reference ID : 3983525, 37 pages . U . S . C . 154 (b ) by 0 days. ORAVIG® (miconazole ) , Highlights of Prescribing Information , Label ; Patient Information approved by the U . S . Food and Drug Administration ; Copyright 2012 Praelia Pharmaceuticals , Inc . , North (21 ) Appl.
    [Show full text]
  • Strategies for Managing Sexual Dysfunction Induced by Antidepressant Medication
    King’s Research Portal DOI: 10.1002/14651858.CD003382.pub3 Document Version Publisher's PDF, also known as Version of record Link to publication record in King's Research Portal Citation for published version (APA): Taylor, M. J., Rudkin, L., Bullemor-Day, P., Lubin, J., Chukwujekwu, C., & Hawton, K. (2013). Strategies for managing sexual dysfunction induced by antidepressant medication. Cochrane Database of Systematic Reviews, (5). https://doi.org/10.1002/14651858.CD003382.pub3 Citing this paper Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections. General rights Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights. •Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research. •You may not further distribute the material or use it for any profit-making activity or commercial gain •You may freely distribute the URL identifying the publication in the Research Portal Take down policy If you believe that this document breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim.
    [Show full text]
  • Addyi Generic Name: Flibanserin Manufacturer
    Brand Name: Addyi Generic Name: Flibanserin Manufacturer: Sprout Pharmaceuticals Drug Class: Central Nervous System Agent, Serotonin Agonist, Dopamine antagonist Uses: Labeled Uses: Indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD) as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is NOT due to: A co-existing medical or psychiatric condition, problems within the relationship, or the effects of a medication or other drug substance. Unlabeled Uses: none. Mechanism of Action: The mechanism of action for flibanserin in the treatment of hypoactive sexual desire disorder is unknown. Flibanserin has high affinity for serotonin (5-hydroxytryptamine or 5-HT) 1A receptors, as an agonist, and 5-HT2A receptors, as an antagonist, and moderate affinity for 5- HT2B, 5-HT2C, and dopamine D4 receptors as an antagonist Pharmacokinetics: Absorption: Tmax 0.75 hours Vd 50L t ½ 11 hours Clearance Not reported Protein binding 98% (albumin) Bioavailability 33% Metabolism: Flibanserin is extensively metabolized primarily by CYP3A4 and, to a lesser extent, CYP2C19 to at least 35 metabolites, with most of the metabolites occurring in low concentrations in plasma. Elimination: Flibanserin is primarily excreted through the kidneys in to urine (44%) and feces (51%). Two metabolites could be characterized that showed plasma concentration similar to that achieved with flibanserin: 6,21-dihydroxy-flibanserin-6,21-disulfate and 6- hydroxy-flibanserin-6-sulfate. These two metabolites are inactive. Efficacy: Katz M, DeRogatis LR, Ackerman R, et al. Efficacy of flibanserin in women with hypoactive sexual desire disorder: results from the BEGONIA trial. J Sex Med.
    [Show full text]
  • Deutetrabenazine
    PATIENT & CAREGIVER EDUCATION Deutetrabenazine This information from Lexicomp® explains what you need to know about this medication, including what it’s used for, how to take it, its side effects, and when to call your healthcare provider. Brand Names: US Austedo Warning This drug may raise the chance of depression and suicidal thoughts or actions in people with Huntington’s disease. If you have ever had depression or suicidal thoughts or actions, talk with your doctor. This drug may not be right for you. People who take this drug must be watched closely. Call your doctor right away if you have signs like depression, nervousness, restlessness, grouchiness, panic attacks, or any other changes in feelings, mood, or behavior. Call your doctor right away if you have any thoughts or actions of suicide. What is this drug used for? It is used to treat disabling involuntary movements in Huntington’s chorea. It is used to treat tardive dyskinesia. What do I need to tell my doctor BEFORE I take this drug? If you are allergic to this drug; any part of this drug; or any other drugs, foods, or substances. Tell your doctor about the allergy and what signs you had. If you have or have ever had depression or thoughts of suicide. Deutetrabenazine 1/6 If you have liver disease. If you have ever had a long QT on ECG or other heartbeat that is not normal. If you have taken certain drugs for depression or Parkinson’s disease in the last 14 days. This includes isocarboxazid, phenelzine, tranylcypromine, selegiline, or rasagiline.
    [Show full text]
  • Different Beta-Blocking Effects of Carvedilol and Bisoprolol in Humans
    Journal of Clinical and Basic Cardiology An Independent International Scientific Journal Journal of Clinical and Basic Cardiology 2001; 4 (1), 53-56 Different beta-blocking effects of carvedilol and bisoprolol in humans Koshucharova G, Klein W, Lercher P, Maier R, Stepan V Stoschitzky K, Zweiker R Homepage: www.kup.at/jcbc Online Data Base Search for Authors and Keywords Indexed in Chemical Abstracts EMBASE/Excerpta Medica Krause & Pachernegg GmbH · VERLAG für MEDIZIN und WIRTSCHAFT · A-3003 Gablitz/Austria ORIGINAL PAPERS, CLINICAL CARDIOLOGY Different Beta-Blocking Effects of Carvedilol and Bisoprolol J Clin Basic Cardiol 2001; 4: 53 Different Beta-Blocking Effects of Carvedilol and Bisoprolol in Humans G. Koshucharova, R. Zweiker, R. Maier, P. Lercher, V. Stepan, W. Klein, K. Stoschitzky Bisoprolol is a beta1-selective beta-adrenergic antagonist while carvedilol is a non-selective beta-blocker with additional blockade of alpha1-adrenoceptors. Administration of bisoprolol has been shown to cause up-regulation of β-adrenoceptor density and to decrease nocturnal melatonin release, whereas carvedilol lacks these typical effects of beta-blocking drugs. The objective of the present study was to investigate beta-blocking effects of bisoprolol and carvedilol in healthy subjects. We compared the effects of single oral doses of clinically recommended amounts of bisoprolol (2.5, 5 and 10 mg) and carvedilol (25, 50 and 100 mg) to those of placebo in a randomised, double-blind, cross-over study in 12 healthy male volun- teers. Three hours after oral administration of the drugs heart rate and blood pressure were measured at rest, after 10 min. of exercise, and after 15 min.
    [Show full text]
  • Tall Man Lettering List REPORT DECEMBER 2013 1
    Tall Man Lettering List REPORT DECEMBER 2013 1 TALL MAN LETTERING LIST REPORT WWW.HQSC.GOVT.NZ Published in December 2013 by the Health Quality & Safety Commission. This document is available on the Health Quality & Safety Commission website, www.hqsc.govt.nz ISBN: 978-0-478-38555-7 (online) Citation: Health Quality & Safety Commission. 2013. Tall Man Lettering List Report. Wellington: Health Quality & Safety Commission. Crown copyright ©. This copyright work is licensed under the Creative Commons Attribution-No Derivative Works 3.0 New Zealand licence. In essence, you are free to copy and distribute the work (including other media and formats), as long as you attribute the work to the Health Quality & Safety Commission. The work must not be adapted and other licence terms must be abided. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nd/3.0/nz/ Copyright enquiries If you are in doubt as to whether a proposed use is covered by this licence, please contact: National Medication Safety Programme Team Health Quality & Safety Commission PO Box 25496 Wellington 6146 ACKNOWLEDGEMENTS The Health Quality & Safety Commission acknowledges the following for their assistance in producing the New Zealand Tall Man lettering list: • The Australian Commission on Safety and Quality in Health Care for advice and support in allowing its original work to be either reproduced in whole or altered in part for New Zealand as per its copyright1 • The Medication Safety and Quality Program of Clinical Excellence Commission, New South
    [Show full text]
  • (Xenazine); Deutetrabenazine (Austedo); Valbenazine
    tetrabenazine (Xenazine ®); deutetrabenazine (Austedo ™); valbenazine (Ingrezza ™) EOCCO POLICY Po licy Type: PA/SP Pharmacy Coverage Policy: EOCCO157 Description Tetrabenazine (Xenazine), deutetrabenazine (Austedo) and valbenazine (Ingrezza) are reversible vesicular monoamine transporter 2 (VMAT2) inhibitors that act by regulating monoamine uptake from the cytoplasm to the synaptic vesicle. Its mechanism of action in Tardive dyskinesia or chorea-reduction is unknown . Length of Authorization Initial (Tardive dyskinesia): Three months Initial (Chorea associated with Huntington’s disease): 12 months Renewal: 12 months Quantity limits Product Name Dosage Form Indication Quantity Limit 12.5 mg Chorea associated with 60 tablets/30 days 25 mg Huntington’s disease Chorea associated with tetrabenazine (Xenazine) Huntington’s disease, 25 mg genotyped extensive 120 tablets/30 days and intermediate metabolizers 12.5 mg Chorea associated with 60 tablets/30 days 25 mg Huntington’s disease Chorea associated with generic tetrabenazine Huntington’s disease, 25 mg genotyped extensive 120 tablets/30 days and intermediate metabolizers 6 mg Tardive dyskinesia in adults; Chorea 30 tablets/30 days deutetrabenazine (Austedo) 9 mg associated with 12 mg Huntington’s disease 120 tablets/30 days 40 mg 30 capsules/30 days; valbenazine (Ingrezza) Tardive Dyskinesia 80 mg 4-week Initiation Pack Initial Evaluation I. Tetrabenazine (Xenazine), deutetrabenazine (Austedo) and valbenazine (Ingrezza) may be considered medically necessary when the following criteria below are met: A. Member is 18 years of age or older; AND B. Medication is prescribed by, or in consultation with, a neurologist or psychiatrist; AND C. Medication will not be used in combination with another VMAT2 inhibitor [e.g. tetrabenazine (Xenazine), deutetrabenazine (Austedo) valbenazine (Ingrezza)], monoamine oxidase inhibitor (MAOI) [e.g.
    [Show full text]
  • TRANDATE® (Labetalol Hydrochloride) Tablets
    NDA 18716/S-026 Page 2 PRODUCT INFORMATION TRANDATE® (labetalol hydrochloride) Tablets DESCRIPTION: Trandate Tablets are adrenergic receptor blocking agents that have both selective alpha1-adrenergic and nonselective beta-adrenergic receptor blocking actions in a single substance. Labetalol hydrochloride (HCl) is a racemate chemically designated as 2-hydroxy-5-[1-hydroxy-2-[(1­ methyl-3-phenylpropyl)amino]ethyl]benzamide monohydrochloride, and it has the following structure: Labetalol HCl has the empirical formula C19H24N2O3•HCl and a molecular weight of 364.9. It has two asymmetric centers and therefore exists as a molecular complex of two diastereoisomeric pairs. Dilevalol, the R,R′ stereoisomer, makes up 25% of racemic labetalol. Labetalol HCl is a white or off-white crystalline powder, soluble in water. Trandate Tablets contain 100, 200, or 300 mg of labetalol HCl and are taken orally. The tablets also contain the inactive ingredients corn starch, FD&C Yellow No. 6 (100- and 300-mg tablets only), hydroxypropyl methylcellulose, lactose, magnesium stearate, pregelatinized corn starch, sodium benzoate (200-mg tablet only), talc (100-mg tablet only), and titanium dioxide. CLINICAL PHARMACOLOGY: Labetalol HCl combines both selective, competitive, alpha1-adrenergic blocking and nonselective, competitive, beta-adrenergic blocking activity in a single substance. In man, the ratios of alpha- to beta-blockade have been estimated to be approximately 1:3 and 1:7 following oral and intravenous (IV) administration, respectively. Beta2-agonist activity has been demonstrated in animals with minimal beta1-agonist (ISA) activity detected. In animals, at doses greater than those required for alpha- or beta-adrenergic blockade, a membrane stabilizing effect has been demonstrated.
    [Show full text]